Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Marinus Pharma CS (MRNS)

Marinus Pharma CS (MRNS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Marinus Pharma CS 100 Matsonford Rd Suite 500 Radnor PA 19087 USA

www.marinuspharma.com P: 484-801-4670

Description:

Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on developing and commercializing therapeutics for the treatment of epilepsy and other targeted neurological, behavioral and psychiatric disorders. The Company offers Ganaxolone which has completed Phase II clinical trial for the treatment of patients with refractory focal onset seizures. Marinus Pharmaceuticals, Inc. is headquartered in New Haven, Connecticut.

Key Statistics

Overview:

Market Capitalization, $K 79,654
Enterprise Value, $K 56,484
Shares Outstanding, K 54,934
Annual Sales, $ 30,990 K
Annual Net Income, $ -141,410 K
Last Quarter Sales, $ 7,680 K
Last Quarter Net Income, $ -38,670 K
EBIT, $ -134,350 K
EBITDA, $ -134,140 K
60-Month Beta 1.11
% of Insider Shareholders 5.46%
% of Institutional Shareholders 98.80%
Float, K 51,935
% Float 94.54%
Short Volume Ratio 0.64

Growth:

1-Year Return -85.54%
3-Year Return -92.44%
5-Year Return -91.27%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 26.94%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.68 on 05/08/24
Next Earnings Date 08/08/24
Earnings Per Share ttm -2.64
EPS Growth vs. Prev Qtr 8.11%
EPS Growth vs. Prev Year -1.49%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 09/23/20

MRNS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -518.13%
Return-on-Assets % -81.85%
Profit Margin % -456.31%
Debt/Equity -5.80
Price/Sales 2.60
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.30
Interest Coverage -7.46
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar